Check the EU approval status of Gefapixant Citrate

Gefapixant Citrate (Gefapixant Citrate) is an innovative drug targeting P2X3 receptors. It is mainly used to treat patients with chronic cough. It reduces the impact of frequent coughing on the quality of life by inhibiting the cough reflex. As one of the first P2X3 receptor antagonists developed specifically for chronic cough, Gemfapixin has received widespread attention around the world, and its efficacy and safety have been verified in multiple clinical studies. In September 2023, Gemfapixin was officially approved in the European Union, becoming the first drug approved in the region for the treatment of chronic cough. This approval marks a new stage in the management of chronic cough, providing a new treatment option for patients suffering from long-term cough.

In clinical application, the significant advantage of Gemfapixin is that it can effectively reduce the number of patients' daily coughs and improve the quality of life. Common side effects during patient use are mainly related to dysgeusia, including loss or change of taste. These side effects are manageable in most cases and usually disappear in the short term once the medication is stopped, without causing long-term health consequences. Because of its good safety profile and manageable side effects, the European Medicines Agency assessed that the benefits of Gemfapixen outweighed the potential risks and approved its use within the EU.

The approval of Gemfapixin in the European market also provides a reference for drug supervision in other regions. The innovative nature of its mechanism makes it uniquely valuable in the treatment of chronic cough. For patients with chronic cough, traditional treatments often have limited effects. P2X3 receptor antagonists directly intervene in the cough neural circuit through targeted effects, providing new possibilities for improving patients' symptoms and daily life. In addition, the drug management of Gemfapixin is relatively simple and can be administered orally, which facilitates long-term use and compliance management of patients.

Reference materials:https://www.medicines.org.uk/emc/product/15778/pil